Prudential Financial Inc. Buys 457,784 Shares of Xeris Biopharma Holdings, Inc. $XERS

Prudential Financial Inc. grew its stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 41.7% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 1,556,629 shares of the company’s stock after buying an additional 457,784 shares during the period. Prudential Financial Inc. owned approximately 0.96% of Xeris Biopharma worth $7,269,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. increased its stake in Xeris Biopharma by 2.7% during the first quarter. Vanguard Group Inc. now owns 8,109,644 shares of the company’s stock valued at $44,522,000 after acquiring an additional 210,581 shares during the period. Geode Capital Management LLC lifted its position in shares of Xeris Biopharma by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 3,650,688 shares of the company’s stock worth $17,052,000 after acquiring an additional 244,862 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after purchasing an additional 1,199,435 shares in the last quarter. Millennium Management LLC increased its position in shares of Xeris Biopharma by 19.0% during the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock valued at $12,726,000 after purchasing an additional 369,420 shares during the period. Finally, Nuveen LLC bought a new stake in shares of Xeris Biopharma during the first quarter valued at approximately $12,240,000. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Trading Up 0.1%

Shares of Xeris Biopharma stock opened at $7.19 on Friday. The stock has a market capitalization of $1.19 billion, a price-to-earnings ratio of -71.84 and a beta of 0.21. Xeris Biopharma Holdings, Inc. has a 1-year low of $3.14 and a 1-year high of $10.08. The firm’s 50-day moving average price is $8.22 and its two-hundred day moving average price is $6.66.

Xeris Biopharma (NASDAQ:XERS) last posted its earnings results on Thursday, November 6th. The company reported $0.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.01). The firm had revenue of $74.38 million for the quarter, compared to the consensus estimate of $74.19 million. Xeris Biopharma has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on XERS shares. Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Saturday, November 8th. Zacks Research downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xeris Biopharma in a research note on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Xeris Biopharma in a research report on Friday, November 7th. Finally, Piper Sandler lifted their price objective on Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Xeris Biopharma currently has an average rating of “Moderate Buy” and a consensus target price of $9.58.

Insiders Place Their Bets

In related news, Director Marla Persky sold 15,500 shares of Xeris Biopharma stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $7.72, for a total value of $119,660.00. Following the completion of the transaction, the director directly owned 142,000 shares of the company’s stock, valued at $1,096,240. The trade was a 9.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Beth Hecht sold 16,667 shares of the company’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $7.40, for a total transaction of $123,335.80. Following the transaction, the insider owned 1,336,843 shares in the company, valued at approximately $9,892,638.20. This trade represents a 1.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 55,409 shares of company stock valued at $416,381. 6.47% of the stock is currently owned by corporate insiders.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.